Status: Recruiting
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).
Participants needed: 200
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Ichnos Sciences SAUpdated: Apr 1, 2026Locations: 32
Eligibility criteria
Participants with pathologically confirmed MM with measurable M-protein: serum a... [+2]
Active malignant central nervous system involvement [+4]